XBiotech financials
$2.18+1.40%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$6.1M | -$6.3M | -$29.8M | -$6.0M | -$6.3M | -$13.6M | -$8.7M | -$7.9M | -$15.0M | -$10.9M | -$8.6M | -$8.5M |
| Net income | -$6.7M | -$5.5M | -$26.9M | -$6.0M | -$1.8M | -$10.9M | -$10.5M | -$5.0M | -$13.0M | -$10.0M | -$4.6M | -$7.4M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.22 | $-0.18 | $-0.88 | $-0.20 | $-0.06 | $-0.36 | $-0.34 | $-0.16 | $-0.43 | $-0.33 | $-0.15 | $-0.24 |
| EBITDA | -$5.8M | -$5.9M | -$29.4M | -$5.6M | -$5.9M | -$13.1M | -$8.3M | -$7.5M | -$14.5M | -$10.4M | -$8.2M | -$8.1M |
| Operating cash flow | -$4.5M | -$9.0M | -$23.0M | -$4.3M | -$6.0M | -$6.7M | -$6.5M | -$5.8M | -$11.4M | -$7.2M | -$3.4M | -$1.5M |
| Free cash flow | -$4.5M | -$9.0M | -$23.0M | -$4.4M | -$6.0M | -$6.8M | -$6.6M | -$6.2M | -$12.0M | -$7.5M | -$3.5M | -$1.5M |
| Diluted shares | 30.5M | 30.5M | 30.5M | 30.5M | 30.5M | 30.5M | 30.5M | 30.5M | 30.5M | 30.4M | 30.4M | 30.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $109.5M | $115.5M | $125.6M | $147.4M | $152.9M | $155.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $133.7M | $139.8M | $150.1M | $172.4M | $178.7M | $181.9M |
| Total liabilities | $5.2M | $4.8M | $9.7M | $5.3M | $5.6M | $7.2M |
| Shareholders' equity | $128.5M | $135.0M | $140.3M | $167.1M | $173.1M | $174.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology